How KCNH2 gene changes affect Long QT and dangerous heart rhythm risk
Integrating KCNH2 Variant-Specific Features and Heterozygote Phenotypes to Estimate Long QT Penetrance
This project combines genetic and health information to estimate how changes in the KCNH2 gene change the chance of Long QT or life‑threatening heart rhythms for people who carry those changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11252786 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers will combine genetic sequencing results, clinical records (including ECGs), and data from autopsy and large biobanks to learn how specific KCNH2 variants relate to Long QT and sudden arrhythmia risk. They will use statistical and Bayesian models that merge variant-specific lab features and the observed symptoms of heterozygous carriers to produce better risk estimates even for very rare variants. The team will examine differences by sex and timing (for example, higher postpartum risk in women) and draw on multi‑site datasets to increase the number of observed carriers. The approach is meant to give clearer, individualized risk information for people found to have KCNH2 changes.
Who could benefit from this research
Good fit: Ideal candidates are people known to carry KCNH2 gene variants, those with a family history of Long QT or unexplained sudden death, or individuals with prolonged QT on an ECG.
Not a fit: People without KCNH2 variants or those whose arrhythmias are caused by unrelated conditions may not receive direct benefit from this work.
Why it matters
Potential benefit: If successful, this work could give clearer, personalized risk estimates to people with KCNH2 variants, helping guide monitoring, medication choices, and family planning.
How similar studies have performed: KCNH2 has long been linked to Long QT in some carriers, but using combined variant features and Bayesian integration to estimate penetrance for rare variants is relatively new and not yet widely validated.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Kroncke, Brett M — Vanderbilt University Medical Center
- Study coordinator: Kroncke, Brett M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.